DK1491524T3 - Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf - Google Patents
Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse derafInfo
- Publication number
- DK1491524T3 DK1491524T3 DK04019299T DK04019299T DK1491524T3 DK 1491524 T3 DK1491524 T3 DK 1491524T3 DK 04019299 T DK04019299 T DK 04019299T DK 04019299 T DK04019299 T DK 04019299T DK 1491524 T3 DK1491524 T3 DK 1491524T3
- Authority
- DK
- Denmark
- Prior art keywords
- androgen receptor
- administration
- selective androgen
- receptor modulator
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
- C07C235/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US64497000A | 2000-08-24 | 2000-08-24 | |
US30008301P | 2001-06-25 | 2001-06-25 | |
PCT/US2001/026328 WO2002016310A1 (en) | 2000-08-24 | 2001-08-23 | Selective androgen receptor modulators and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1491524T3 true DK1491524T3 (da) | 2009-05-04 |
Family
ID=26971579
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04019299T DK1491524T3 (da) | 2000-08-24 | 2001-08-23 | Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf |
DK01964368T DK1401801T3 (da) | 2000-08-24 | 2001-08-23 | Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01964368T DK1401801T3 (da) | 2000-08-24 | 2001-08-23 | Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf |
Country Status (21)
Country | Link |
---|---|
US (1) | US6569896B2 (da) |
EP (4) | EP2284149A1 (da) |
JP (2) | JP2004518617A (da) |
KR (1) | KR20030061783A (da) |
CN (2) | CN1736371B (da) |
AT (2) | ATE423092T1 (da) |
AU (2) | AU8523001A (da) |
BR (1) | BR0114801A (da) |
CA (1) | CA2420279C (da) |
CY (2) | CY1105956T1 (da) |
DE (2) | DE60124322T2 (da) |
DK (2) | DK1491524T3 (da) |
EA (2) | EA007101B1 (da) |
ES (2) | ES2321933T3 (da) |
GE (1) | GEP20053586B (da) |
HK (2) | HK1062011A1 (da) |
HR (1) | HRP20030118B1 (da) |
MX (1) | MXPA03001632A (da) |
PT (2) | PT1401801E (da) |
SI (1) | SI1401801T1 (da) |
WO (1) | WO2002016310A1 (da) |
Families Citing this family (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6995284B2 (en) | 2000-08-24 | 2006-02-07 | The University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US6071957A (en) * | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
US7518013B2 (en) | 2000-08-24 | 2009-04-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators |
US20050038110A1 (en) * | 2000-08-24 | 2005-02-17 | Steiner Mitchell S. | Selective androgen receptor modulators and methods of use thereof |
US7759520B2 (en) | 1996-11-27 | 2010-07-20 | University Of Tennessee Research Foundation | Synthesis of selective androgen receptor modulators |
US20040186185A1 (en) * | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
KR20020067545A (ko) * | 1999-12-16 | 2002-08-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 레플루노마이드의 신규 제조 방법 및 이의 신규 결정형 |
US7855229B2 (en) | 2000-08-24 | 2010-12-21 | University Of Tennessee Research Foundation | Treating wasting disorders with selective androgen receptor modulators |
US8445534B2 (en) | 2000-08-24 | 2013-05-21 | University Of Tennessee Research Foundation | Treating androgen decline in aging male (ADAM)-associated conditions with SARMs |
US8008348B2 (en) * | 2001-12-06 | 2011-08-30 | University Of Tennessee Research Foundation | Treating muscle wasting with selective androgen receptor modulators |
US6998500B2 (en) | 2000-08-24 | 2006-02-14 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US7919647B2 (en) | 2000-08-24 | 2011-04-05 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US20040260108A1 (en) * | 2001-06-25 | 2004-12-23 | Dalton James T. | Metabolites of selective androgen receptor modulators and methods of use thereof |
US7645898B2 (en) * | 2000-08-24 | 2010-01-12 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and method of use thereof |
US6838484B2 (en) | 2000-08-24 | 2005-01-04 | University Of Tennessee Research Foundation | Formulations comprising selective androgen receptor modulators |
US7026500B2 (en) * | 2000-08-24 | 2006-04-11 | University Of Tennessee Research Foundation | Halogenated selective androgen receptor modulators and methods of use thereof |
US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US20070173546A1 (en) * | 2000-08-24 | 2007-07-26 | Dalton James T | Selective androgen receptor modulators and method of use thereof |
US7026484B2 (en) * | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
US20060004042A1 (en) * | 2001-08-23 | 2006-01-05 | Dalton James T | Formulations comprising selective androgen receptor modulators |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
MXPA04005519A (es) * | 2001-12-06 | 2005-06-20 | Gtx Inc | Tratamiento del desgaste muscular con moduladores receptores de androgeno selectivos. |
US20070161608A1 (en) * | 2001-12-06 | 2007-07-12 | Dalton James T | Selective androgen receptor modulators for treating muscle wasting |
US8853266B2 (en) | 2001-12-06 | 2014-10-07 | University Of Tennessee Research Foundation | Selective androgen receptor modulators for treating diabetes |
RS69704A (en) | 2002-02-07 | 2006-12-15 | Gtx Inc. | Treating bening prostate hyperplasia with sarms |
US7803970B2 (en) * | 2002-02-28 | 2010-09-28 | University Of Tennessee Research Foundation | Multi-substitued selective androgen receptor modulators and methods of use thereof |
CA2476657A1 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Haloacetamide and azide substituted compounds and methods of use thereof |
US7772433B2 (en) | 2002-02-28 | 2010-08-10 | University Of Tennessee Research Foundation | SARMS and method of use thereof |
EP2266577B8 (en) * | 2002-02-28 | 2015-01-21 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
WO2003074450A2 (en) * | 2002-02-28 | 2003-09-12 | The University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
IL163742A0 (en) * | 2002-02-28 | 2005-12-18 | Univ Tennessee Res Foundation | Irreversible selective androgen receptor modulators and methods of use thereof |
IL163744A0 (en) * | 2002-02-28 | 2005-12-18 | Univ Tennessee Res Foundation | Multi-substituted selective and rogenreceptor modulators and methods of use thereof |
US7705182B2 (en) * | 2002-02-28 | 2010-04-27 | University Of Tennessee Research Foundation | Multi-substituted selective androgen receptor modulators and methods of use thereof |
US7741371B2 (en) * | 2002-06-17 | 2010-06-22 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
TW200407280A (en) * | 2002-06-17 | 2004-05-16 | Univ Tennessee Res Foundation | N-bridged selective androgen receptor modulators and methods of use thereof |
CA2502209A1 (en) * | 2002-10-15 | 2004-04-29 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
AU2003287076C1 (en) * | 2002-10-15 | 2010-03-04 | University Of Tennessee Research Foundation | Heterocyclic selective androgen receptor modulators and methods of use thereof |
JP2006505564A (ja) * | 2002-10-16 | 2006-02-16 | ジーティーエックス・インコーポレイテッド | Sarmによる高齢男性のアンドロゲン減少に関連する病気の治療 |
US20060276539A1 (en) * | 2002-10-16 | 2006-12-07 | Dalton James T | Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS |
US20040087810A1 (en) * | 2002-10-23 | 2004-05-06 | Dalton James T. | Irreversible selective androgen receptor modulators and methods of use thereof |
US8309603B2 (en) | 2004-06-07 | 2012-11-13 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
PT1592658E (pt) * | 2003-01-13 | 2013-06-25 | Univ Tennessee Res Foundation | Síntese em larga escala de modulador selectivo de receptor de androgénio |
AU2004206909A1 (en) * | 2003-01-22 | 2004-08-05 | Gtx Inc. | Treating androgen deficiency in female (ADIF)-associated conditions with sarms |
US20040167103A1 (en) * | 2003-02-24 | 2004-08-26 | Dalton James T. | Haloacetamide and azide substituted compounds and methods of use thereof |
DK1656360T3 (da) * | 2003-06-13 | 2007-12-27 | Janssen Pharmaceutica Nv | Thiazolinderivater som selektive androgenreceptor-modulatorer |
CN100462353C (zh) * | 2003-06-27 | 2009-02-18 | 奥赖恩公司 | 用作雄激素受体调节剂的丙酰胺衍生物 |
DE602004026583D1 (de) * | 2003-06-27 | 2010-05-27 | Orion Corp | Als androgenrezeptormodulatoren geeignete propionamidderivate |
FI20030958A0 (fi) * | 2003-06-27 | 2003-06-27 | Orion Corp | Uusia yhdisteitä |
AU2004266160A1 (en) * | 2003-08-22 | 2005-03-03 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
JP2007508386A (ja) * | 2003-10-14 | 2007-04-05 | ジーティーエックス・インコーポレイテッド | 選択的アンドロゲン受容体調節剤による骨関連疾患の治療 |
GB0324551D0 (en) * | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
US7202234B2 (en) | 2003-10-24 | 2007-04-10 | Eisai Co., Ltd. | Compounds and methods for treating Toll-like receptor 2-related diseases and conditions |
EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
KR20060115325A (ko) * | 2003-12-16 | 2006-11-08 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 모듈레이터의 프로드럭 및 그의이용 방법 |
EP1725522B1 (en) * | 2004-03-03 | 2014-09-10 | GlaxoSmithKline LLC | Aniline derivatives as selective androgen receptor modulators |
US8519158B2 (en) * | 2004-03-12 | 2013-08-27 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
ES2371170T3 (es) * | 2004-05-03 | 2011-12-28 | Janssen Pharmaceutica Nv | Derivados de benzofurano comomoduladores selectivos de receptores de andrógenos (msra). |
US20080045504A1 (en) * | 2004-05-11 | 2008-02-21 | Pfizer Products Inc. | Benzonitrile Derivatives to Treat Musculoskeletal Frailty |
CN102976973B (zh) * | 2004-06-07 | 2015-10-21 | 田纳西大学研究基金会 | 选择性雄激素受体调节剂及其使用方法 |
US9884038B2 (en) | 2004-06-07 | 2018-02-06 | University Of Tennessee Research Foundation | Selective androgen receptor modulator and methods of use thereof |
AU2005251781C1 (en) * | 2004-06-07 | 2008-02-21 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
US20110237664A1 (en) * | 2004-06-07 | 2011-09-29 | Dalton James T | Selective androgen receptor modulators for treating diabetes |
US9889110B2 (en) | 2004-06-07 | 2018-02-13 | University Of Tennessee Research Foundation | Selective androgen receptor modulator for treating hormone-related conditions |
MXPA06015169A (es) * | 2004-07-08 | 2007-08-21 | Warner Lambert Co | Moduladores de androgenos. |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
JP5203712B2 (ja) | 2005-01-10 | 2013-06-05 | アカディア ファーマシューティカルズ インコーポレイテッド | 選択的アンドロゲン受容体モジュレータとしてのアミノフェニル誘導体 |
US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
BRPI0609191B8 (pt) * | 2005-06-17 | 2021-05-25 | Ligand Pharm Inc | métodos e compostos moduladores de receptor de androgênio |
EP1931199A4 (en) * | 2005-08-31 | 2009-07-29 | Univ Tennessee Res Foundation | TREATMENT OF RENAL DISEASE, BURNS, INJURIES OR SPINAL CORD INJURY USING ANDROGEN RECEPTOR SELECTIVE MODULATORS |
EP1945224B1 (en) | 2005-10-19 | 2012-05-02 | Chavah Pty Ltd | Reduction of side effects from aromatase inhibitors used for treating breast cancer |
US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
US20090175845A1 (en) * | 2005-10-25 | 2009-07-09 | The Trustees Of Columbia University In The City Of New York | Methods for identifying compounds that modulate phb domain protein activity and compositions thereof |
US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
US9267937B2 (en) * | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
CA2652280C (en) | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US10010521B2 (en) | 2006-08-24 | 2018-07-03 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
DK2054049T3 (da) | 2006-08-24 | 2016-08-01 | Univ Tennessee Res Found | Substituerede acylanilider og fremgangsmåder til anvendelse deraf |
US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
US9730908B2 (en) | 2006-08-24 | 2017-08-15 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
EA019849B1 (ru) * | 2006-08-28 | 2014-06-30 | Юниверсити Оф Теннесси Рисерч Фаундейшн | Способ лечения, подавления, ингибирования или уменьшения инцидентов симптомов, ассоциированных с почечным заболеванием: гипогонадизма и непроизвольной потери веса |
CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
US9217129B2 (en) * | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
WO2008124634A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
CN101284795B (zh) * | 2007-04-09 | 2012-04-25 | 中国科学院上海药物研究所 | 一类非甾体雄激素受体调节剂及其医学用途 |
US7968603B2 (en) | 2007-09-11 | 2011-06-28 | University Of Tennessee Research Foundation | Solid forms of selective androgen receptor modulators |
HUE036762T2 (hu) * | 2007-09-11 | 2018-07-30 | Gtx Inc | A szelektív androgén modulátor (R) vagy (S)-N-(4-ciano-3-(trifluor-metil)-fenil-3-(4-ciano-fenoxi)-2-hidroxi-2-metil-propánamid kristályos polimorfja |
HUE035101T2 (hu) | 2007-09-28 | 2018-05-02 | Pfizer | Ráksejtek célzása nanorészecskék alkalmazásával |
AU2008314647B2 (en) | 2007-10-12 | 2013-03-21 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US8354446B2 (en) * | 2007-12-21 | 2013-01-15 | Ligand Pharmaceuticals Incorporated | Selective androgen receptor modulators (SARMs) and uses thereof |
WO2009105214A2 (en) | 2008-02-22 | 2009-08-27 | Radius Health, Inc. | Selective androgen receptor modulators |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
WO2010002075A1 (en) * | 2008-07-02 | 2010-01-07 | Pharmacostech Co., Ltd. | Methods for preparing amide derivatives |
US8277812B2 (en) * | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
WO2010093601A1 (en) | 2009-02-10 | 2010-08-19 | Metabasis Therapeutics, Inc. | Novel sulfonic acid-containing thyromimetics, and methods for their use |
JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
LT2568806T (lt) | 2010-05-12 | 2016-09-26 | Radius Health, Inc. | Terapiniai režimai |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
JP5965909B2 (ja) | 2010-09-28 | 2016-08-10 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
WO2012071340A1 (en) | 2010-11-23 | 2012-05-31 | Metamagnetics Inc. | Antenna module having reduced size, high gain, and increased power efficiency |
CN104736569A (zh) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
US20150057452A1 (en) | 2012-04-04 | 2015-02-26 | Catylix, Inc. | Selective androgen receptor modulators |
KR102238970B1 (ko) | 2012-07-13 | 2021-04-09 | 지티엑스, 인코포레이티드 | 선택적 안드로겐 수용체 조절자(sarms)를 이용한 안드로겐 수용체(ar) 양성 유방암의 치료 방법 |
US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
RU2510392C1 (ru) * | 2012-12-21 | 2014-03-27 | Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) | Сокристаллическая форма бикалутамида |
EP3613418A1 (en) | 2014-01-17 | 2020-02-26 | Ligand Pharmaceuticals, Inc. | Methods and compositions for modulating hormone levels |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
EP3834824A1 (en) | 2014-03-28 | 2021-06-16 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
KR20190077607A (ko) * | 2014-10-16 | 2019-07-03 | 지티엑스, 인코포레이티드 | Sarm을 이용하는 비뇨기 장애의 치료 방법 |
CN113633644A (zh) | 2014-10-22 | 2021-11-12 | 哈瓦赫治疗有限公司 | 降低乳房摄影乳腺密度和/或乳腺癌风险的方法 |
WO2016079522A1 (en) | 2014-11-20 | 2016-05-26 | University College Cardiff Consultants Limited | Androgen receptor modulators and their use as anti-cancer agents |
WO2016079521A1 (en) | 2014-11-20 | 2016-05-26 | University College Cardiff Consultants Limited | Androgen receptor modulators and their use as anti-cancer agents |
US10654809B2 (en) | 2016-06-10 | 2020-05-19 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
US10806720B2 (en) | 2015-04-21 | 2020-10-20 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
AU2016252753A1 (en) | 2015-04-21 | 2017-11-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10017471B2 (en) | 2015-04-21 | 2018-07-10 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US9834507B2 (en) | 2015-04-21 | 2017-12-05 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10865184B2 (en) | 2015-04-21 | 2020-12-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10093613B2 (en) | 2015-04-21 | 2018-10-09 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US9815776B2 (en) | 2015-04-21 | 2017-11-14 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
US10035763B2 (en) | 2015-04-21 | 2018-07-31 | Gtx, Inc. | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
JP2018534291A (ja) | 2015-10-22 | 2018-11-22 | ハバフ セラピューティクス ピーティーワイ エルティーディー | マンモグラフィ乳房密度及び/又は乳癌のリスクを低下させる方法 |
US11230523B2 (en) | 2016-06-10 | 2022-01-25 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) ligands and methods of use thereof |
KR102397890B1 (ko) | 2016-06-22 | 2022-05-12 | 일립시스 파마 리미티드 | Ar+ 유방암 치료 방법 |
WO2018129419A1 (en) | 2017-01-05 | 2018-07-12 | Radius Pharmaceuticals, Inc. | Polymorphic forms of rad1901-2hcl |
JP2021523151A (ja) | 2018-05-11 | 2021-09-02 | ホスホレックス、インコーポレイテッド | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
EP3976048A4 (en) | 2019-06-03 | 2023-07-12 | Havah Therapeutics Pty Ltd | PHARMACEUTICAL FORMULATIONS AND SYSTEMS FOR THE ADMINISTRATION OF AN ANDROGEN AGENT AND AN AROMATASE INHIBITOR, AND METHODS OF USE |
MX2023004101A (es) | 2020-10-08 | 2023-10-11 | Targimmune Therapeutics Ag | Inmunoterapia para el tratamiento de cancer. |
EP4001293A1 (de) * | 2020-11-23 | 2022-05-25 | Justus-Liebig-Universität Gießen | Tetrapeptid und dessen verwendung |
CN116801872A (zh) * | 2021-02-10 | 2023-09-22 | 上海奕拓医药科技有限责任公司 | 调节雄激素受体凝聚物的方法 |
WO2023079142A2 (en) | 2021-11-05 | 2023-05-11 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100040A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Psma-targeting linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100046A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Targeted linear conjugates comprising polyethyleneimine and polyethylene glycol and polyplexes comprising the same |
WO2024100044A1 (en) | 2022-11-07 | 2024-05-16 | Targimmune Therapeutics Ag | Polyplexes of nucleic acids and targeted conjugates comprising polyethyleneimine and polyethylene glycol |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3875229A (en) | 1972-11-24 | 1975-04-01 | Schering Corp | Substituted carboxanilides |
US4139638A (en) | 1976-09-23 | 1979-02-13 | Schering Corporation | Methods for the treatment of hirsutism |
EP0002309B1 (en) | 1977-10-12 | 1982-12-01 | Imperial Chemical Industries Plc | Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them |
US4191775A (en) | 1977-12-15 | 1980-03-04 | Imperial Chemical Industries Limited | Amide derivatives |
NZ197008A (en) | 1980-05-22 | 1984-10-19 | Ici Ltd | Acylanilide derivatives and pharmaceutical compositions |
JPS57171904A (en) | 1981-04-15 | 1982-10-22 | Mitsubishi Petrochem Co Ltd | Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide |
DE3372965D1 (en) * | 1982-07-23 | 1987-09-17 | Ici Plc | Amide derivatives |
GB8617652D0 (en) | 1986-07-18 | 1986-08-28 | Ici Plc | Acylanilide derivatives |
GB8617653D0 (en) * | 1986-07-18 | 1986-08-28 | Ici Plc | Amide derivatives |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
JPH09508125A (ja) | 1994-01-21 | 1997-08-19 | セプラコー,インコーポレイテッド | 光学的純正r−(−)−カソデックスを使用した男性ホルモン依存疾患治療のための方法と組成 |
US5609849A (en) | 1994-03-11 | 1997-03-11 | The Trustees Of The University Of Pennsylvania | Serotonin (5-HT1A) receptor ligands and imaging agents |
US5656651A (en) | 1995-06-16 | 1997-08-12 | Biophysica Inc. | Androgenic directed compositions |
TW397821B (en) * | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
US6071957A (en) | 1996-11-27 | 2000-06-06 | The University Of Tennessee Research Corporation | Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer |
WO1998053826A1 (en) * | 1997-05-30 | 1998-12-03 | The University Of Tennessee Research Corporation | Non-steroidal agonist compounds and their use in male hormone therapy |
AU7723198A (en) | 1997-06-04 | 1998-12-21 | University Of Tennessee Research Corporation, The | Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging |
-
2001
- 2001-08-23 PT PT01964368T patent/PT1401801E/pt unknown
- 2001-08-23 ES ES04019299T patent/ES2321933T3/es not_active Expired - Lifetime
- 2001-08-23 CN CN2005100674946A patent/CN1736371B/zh not_active Expired - Fee Related
- 2001-08-23 EA EA200300283A patent/EA007101B1/ru not_active IP Right Cessation
- 2001-08-23 AU AU8523001A patent/AU8523001A/xx active Pending
- 2001-08-23 EP EP10182881A patent/EP2284149A1/en not_active Withdrawn
- 2001-08-23 MX MXPA03001632A patent/MXPA03001632A/es active IP Right Grant
- 2001-08-23 AT AT04019299T patent/ATE423092T1/de active
- 2001-08-23 GE GE5108A patent/GEP20053586B/en unknown
- 2001-08-23 AT AT01964368T patent/ATE344233T1/de active
- 2001-08-23 EP EP01964368A patent/EP1401801B1/en not_active Expired - Lifetime
- 2001-08-23 DK DK04019299T patent/DK1491524T3/da active
- 2001-08-23 SI SI200130685T patent/SI1401801T1/sl unknown
- 2001-08-23 EA EA200501269A patent/EA014224B1/ru not_active IP Right Cessation
- 2001-08-23 EP EP06014580A patent/EP1705174A1/en not_active Withdrawn
- 2001-08-23 CN CNB018178898A patent/CN1230418C/zh not_active Expired - Fee Related
- 2001-08-23 KR KR10-2003-7002652A patent/KR20030061783A/ko not_active Application Discontinuation
- 2001-08-23 US US09/935,045 patent/US6569896B2/en not_active Expired - Fee Related
- 2001-08-23 AU AU2001285230A patent/AU2001285230C1/en not_active Ceased
- 2001-08-23 JP JP2002521186A patent/JP2004518617A/ja active Pending
- 2001-08-23 CA CA2420279A patent/CA2420279C/en not_active Expired - Lifetime
- 2001-08-23 BR BR0114801-0A patent/BR0114801A/pt not_active IP Right Cessation
- 2001-08-23 DE DE60124322T patent/DE60124322T2/de not_active Expired - Lifetime
- 2001-08-23 PT PT04019299T patent/PT1491524E/pt unknown
- 2001-08-23 WO PCT/US2001/026328 patent/WO2002016310A1/en active Application Filing
- 2001-08-23 EP EP04019299A patent/EP1491524B1/en not_active Expired - Lifetime
- 2001-08-23 ES ES01964368T patent/ES2275717T3/es not_active Expired - Lifetime
- 2001-08-23 DE DE60137728T patent/DE60137728D1/de not_active Expired - Lifetime
- 2001-08-23 DK DK01964368T patent/DK1401801T3/da active
-
2003
- 2003-02-19 HR HR20030118A patent/HRP20030118B1/xx not_active IP Right Cessation
-
2004
- 2004-07-08 HK HK04104977A patent/HK1062011A1/xx not_active IP Right Cessation
-
2005
- 2005-05-12 HK HK05103982.9A patent/HK1072243A1/xx not_active IP Right Cessation
-
2006
- 2006-05-29 JP JP2006147596A patent/JP2006306880A/ja active Pending
-
2007
- 2007-01-26 CY CY20071100104T patent/CY1105956T1/el unknown
-
2009
- 2009-05-08 CY CY20091100497T patent/CY1110459T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1401801T3 (da) | Selektive androgenreceptormodulatorer og fremgangsmåder til anvendelse deraf | |
KR910009235A (ko) | 4-히드록시인돌에서 유도된 산화염색 선구물질 및 결합제와 들어있는 케라틴 섬유 염색 조성물 및 이것을 이용한 염색 방법. | |
EA200000155A2 (ru) | 4-фенилпиридиновые производные | |
JP3289900B2 (ja) | メタ−アミノフェノール、ケラチン繊維の酸化染色用カップリング剤としてその使用、染色組成物および方法 | |
NL300180I1 (nl) | Toepassen van toxmoxetine voor het behandelen van concentratiestroornis/hyperactiviteit aandoening. | |
CA2359244A1 (en) | .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | |
BRPI0511308B8 (pt) | moduladores seletivos receptores de androgênio e seus métodos de uso | |
UY28269A1 (es) | Compuestos que modulan la actividad de ppar y procedimientos de preparación | |
JP2719514B2 (ja) | 2,4−ジアミノ−1,3−ジメトキシベンゼンの製造法 | |
CO4950515A1 (es) | Nuevos derivados de la quinolina para uso medicinal | |
JPS5344544A (en) | Substituted phenylurea derivatives, their preparation, and selective herbicide comprising the corresponding compounds | |
IL126110A0 (en) | Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use | |
FI945581A (fi) | Substituoidut (aryylialkoksibentsyyli) aminopropaaniamidijohdannaiset, niiden valmistus ja käyttö antiepileptisinä, neuroprotektiivisina ja antidepressiivisinä aineina | |
ES2167853T3 (es) | N-aril 2-hidroxi alquilamidas. | |
JP2017514788A (ja) | 酸化剤組成物およびuv可視放射線を用いてケラチン繊維を脱色または染色するための方法 | |
AUPR118000A0 (en) | Therapeutic molecules and methods | |
DK0821952T3 (da) | Anvendelse af isoxazol- og crotonsyreamidderivater til modulering af apoptose | |
JP2002541102A5 (da) | ||
FI945582A0 (fi) | Substituoidut (aryylialkyyliaminobentsyyli) aminopropioniamidijohdannaiset, niiden valmistus ja käyttö anti-epileptisinä, neuroprotektiivisina ja antidepressiivisina aineina | |
AR020121A1 (es) | Derivados de 1,3-oxazol, composicion farmaceutica que los comprende, procedimiento para la preparacion de dichos derivados y el uso de los mismospara la elaboracion de medicamentos utiles como antagonistas del receptor de vitronectina. | |
YU16196A (sh) | Upotreba novih benzohinolin-3-ona i njihovih farmaceutski prihvatljivih soli za proizvodnju leka | |
BR8405275A (pt) | Compostos piretroides,composicao inseticida e processo de combate de pragas de insetos em um local e processo para preparar um composto piretroide | |
JPS5392763A (en) | Sulfoneamide type benzamide derivatives | |
UA38563A (uk) | Спосіб йодування кухонної солі | |
NO972942L (no) | 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende disse forbindelsene og deres anvendelse |